Pollard Banknote Ltd. v. BABN Technologies Corp. et al., 2016 FC 883

JurisdictionFederal Jurisdiction (Canada)
JudgeLocke, J.
CourtFederal Court (Canada)
Subject MatterPATENTS OF INVENTION
Date28 July 2016
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
40 practice notes
  • Aux Sable Liquid Products LP c. JL Energy Transportation Inc.,
    • Canada
    • Federal Court (Canada)
    • May 6, 2019
    ...Water Treatments Limited v. SNF Inc., 2017 FCA 225 , 152 C.P.R. (4th) 239 ; Pollard Banknote Limited v. BABN Technologies Corp., 2016 FC 883, 141 C.P.R. (4th) 329; Teva Canada Ltd. v. Pzer Canada Inc., 2012 SCC 60 , [2012] 3 S.C.R. 625 ; AbbVie Biotechnology Ltd. v. Canada (Atto......
  • Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research, 2018 FC 259
    • Canada
    • Federal Court (Canada)
    • March 7, 2018
    ...the common general knowledge of the POSITA is the claim date of August 1, 1996 (Pollard Banknote Limited v BABN Technologies Corp, 2016 FC 883 at para 153, 141 CPR (4th) 329). [82] This is one of the hotly contested issues in this litigation. Hospira placed considerable importance on this i......
  • Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
    • Canada
    • Federal Court (Canada)
    • April 7, 2022
    ...Life Science Ventures, LLC v Pfizer Canada ULC, 2020 FC 1, para 173; see also Pollard Banknote Limited v BABN Technologies Corp., 2016 FC 883, para 146; Amfac Foods Inc v Irving Pulp & Paper, Ltd (1986), 12 CPR (3d) 193 at 201-205 (FCA), paras 32-33). (2) Analysis (a) The 384 and 421 Pa......
  • Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
    • Canada
    • Federal Court (Canada)
    • September 10, 2020
    ...Examiner found that such initial claims were invalid for claiming a method of medical treatment (Pollard Banknote v BABN Technology, 2016 FC 883 [Pollard]). Finally, the Defendants outline that the 684 Patent was listed against Lilly’s ADCIRCA product on the Patent Register, although ADCIRC......
  • Request a trial to view additional results
19 cases
  • Aux Sable Liquid Products LP c. JL Energy Transportation Inc.,
    • Canada
    • Federal Court (Canada)
    • May 6, 2019
    ...Water Treatments Limited v. SNF Inc., 2017 FCA 225 , 152 C.P.R. (4th) 239 ; Pollard Banknote Limited v. BABN Technologies Corp., 2016 FC 883, 141 C.P.R. (4th) 329; Teva Canada Ltd. v. Pzer Canada Inc., 2012 SCC 60 , [2012] 3 S.C.R. 625 ; AbbVie Biotechnology Ltd. v. Canada (Atto......
  • Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research, 2018 FC 259
    • Canada
    • Federal Court (Canada)
    • March 7, 2018
    ...the common general knowledge of the POSITA is the claim date of August 1, 1996 (Pollard Banknote Limited v BABN Technologies Corp, 2016 FC 883 at para 153, 141 CPR (4th) 329). [82] This is one of the hotly contested issues in this litigation. Hospira placed considerable importance on this i......
  • Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
    • Canada
    • Federal Court (Canada)
    • April 7, 2022
    ...Life Science Ventures, LLC v Pfizer Canada ULC, 2020 FC 1, para 173; see also Pollard Banknote Limited v BABN Technologies Corp., 2016 FC 883, para 146; Amfac Foods Inc v Irving Pulp & Paper, Ltd (1986), 12 CPR (3d) 193 at 201-205 (FCA), paras 32-33). (2) Analysis (a) The 384 and 421 Pa......
  • Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
    • Canada
    • Federal Court (Canada)
    • September 10, 2020
    ...Examiner found that such initial claims were invalid for claiming a method of medical treatment (Pollard Banknote v BABN Technology, 2016 FC 883 [Pollard]). Finally, the Defendants outline that the 684 Patent was listed against Lilly’s ADCIRCA product on the Patent Register, although ADCIRC......
  • Request a trial to view additional results
17 firm's commentaries

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT